ARTS-876 / Allorion Therap - LARVOL DELTA

Preclinical evaluation of ARTS-876, an AKR1C3-activated prodrug targeting KEAP1/NFE2L2-mutant NSCLC (AACR 2026) - "In contrast, minimal inhibition was observed in wild-type CDX and PDX models. Furthermore, ARTS-876 enhances antitumor immunity by increasing intratumoral CD3+ and CD8+ T-cell infiltration as monotherapy and shows combinatorial efficacy with anti-PD-1 antibodies without additive toxicity, providing a rationale for combination with immune checkpoint inhibitors A first-in-human Phase 1a/1b trial in advanced NSCLC harboring KEAP1/NFE2L2 alterations is currently ongoing in China."

First-in-human • IO biomarker • Late-breaking abstract • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AKR1C3 • CD8 • KEAP1 • NFE2L2